Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Inclusion Criteria: Diagnosis of multiple myeloma Stage II or III disease Relapsed disease after ≥ 2 prior therapies*, confirmed by the presence of 1 of the following: New lytic lesion A 25% increase in urine or serum monoclonal protein Patients who received prior bortezomib must have responded to therapy Measurable disease, defined by 1 or more of the following criteria: Serum M-component ≥ 1.0 g/dL by serum protein electrophoresis Urine M-protein excretion > 200 mg per 24-hour collection, by urine protein electrophoresis Performance status - Karnofsky 60-100% More than 8 weeks Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,000/mm^3 Bilirubin ≤ 2 mg/dL Direct bilirubin ≤ 2 times upper limit of normal (ULN) AST or ALT ≤ 2 times ULN Creatinine ≤ 1.5 times ULN Calcium ≤ 12 mg/dL Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Able to swallow study medication Capable of following directions regarding study medication, or has a daily caregiver who will be responsible for administering study medication No peripheral neuropathy ≥ grade 2 No hypersensitivity to any of the following: Bortezomib Boron Mannitol Imidazole compounds (e.g., clotrimazole, ketoconazole, miconazole, econazole) No serious medical or psychiatric illness that would preclude study compliance No other life-threatening illness (unrelated to tumor) No other active or invasive malignancy within the past 3 years except for nonmelanoma skin cancer No serious infection No prior allogeneic bone marrow transplantation More than 30 days since prior and no concurrent immunotherapy More than 30 days since prior and no concurrent cytotoxic chemotherapy More than 14 days since prior high-dose corticosteroids No concurrent therapeutic corticosteroids (e.g., > 10 mg prednisone per day) No concurrent hormonal therapy No concurrent antiemetic corticosteroids More than 14 days since prior and no concurrent radiotherapy More than 1 year since prior bortezomib More than 14 days since prior investigational drugs No prior tipifarnib No other concurrent cancer-related treatment No concurrent administration of the following enzyme-inducing anti-epileptic drugs: Phenytoin Phenobarbital Carbamazepine No concurrent magnesium- or aluminum-based antacids within 2 hours before or after tipifarnib administration Concurrent pamidronate or other bisphosphonates allowed